Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 2Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 44Gastrointestinal 3Thoracic 2Lymphoid 2Genitourinary 2Other hematologic neoplasm 1Gynecologic 1CNS 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 65Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 41Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 30Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Triptorelin Pamoate 23Sunitinib 23Nivolumab 23Radiation 22apalutamide 21Doxorubicin 20darolutamide 18Gonadotropin-Releasing Hormone 18cabozantinib 16abiraterone 16Specimen Handling 16Radiosurgery 16Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Thalidomide × Genitourinary × Clear all
NCT00004635 2018-05-22

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
159 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00005966 2009-02-05

Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡